Nurix Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1700 Owens St Ste 205, San Francisco, Ca...Phone Number
(415) 660-5320Website
www.nurixtx.comRevenue
$36.8 MillionStock Symbol
NRIXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nurix Therapeutics
Nurix Therapeutics founded in 2009 and headquartered in San Francisco, California, develops therapies that control disease-causing proteins and develops drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer.Explore more
Nurix Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nurix Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Nurix Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Nurix Therapeutics
Check out if Nurix Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Nurix Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nurix Therapeutics recently announced quarterly report
Nurix Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Nurix Therapeutics launches new products
Click to see if Nurix Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Nurix Therapeutics
Find 3 more new buyers
Compare Similar Companies to Nurix Therapeutics
Compare insights from companies similar to Nurix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nurix Therapeutics
$36.8M
201-500
Public
$354.1M
2009
CR
Christine RingChief Legal Officer and Chief Compliance Officer
Company Profile Activity
Activity Insights
Nurix Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nurix Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nurix Therapeutics.
Nurix Therapeutics financials insights
Gather financial insights about Nurix Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series B
$25.1M
2020
Other Financing Round
$120M
Stock Offering
$209M
Nurix Therapeutics Tech Stack
A closer look at the technologies used by Nurix Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Earnings
Earnings, Finance
Nurix Therapeutics News & Media
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront paymentA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
Issued on behalf of GT Biopharma, Inc. GT Biopharma, Inc. (NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development...Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nurix Therapeutics
Sign Up For FreeTo access detailed company insights
Nurix Therapeutics founded in 2009 and headquartered in San Francisco, California, develops therapies that control disease-causing proteins and develops drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer.... Read More
